The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2020 was US$0.95 per share, up 12%.
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 …
Osaka, JAPAN, and King of Prussia, PA, USA Partnership brings together world-leading plasma companies to focus on developi…
CSL continues to provide medicines to patients around the world.
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
CSL Limited's statement on Coronavirus
Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across si…
Chief Executive Officer and Managing Director Paul Perreault presented the company's overview on Monday, January 13, at 3:30 …
Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Dev…
CSL statement in response to media reports on case against Joseph Chiao
Popular search terms:
Americas
Asia Pacific
Europe
